Difference between revisions of "Urothelial carcinoma"
(→Plasmacytoid urothelial cell carcinoma: split out) |
|||
(36 intermediate revisions by 2 users not shown) | |||
Line 3: | Line 3: | ||
| Image = Urothelial carcinoma positive margin -- high mag.jpg | | Image = Urothelial carcinoma positive margin -- high mag.jpg | ||
| Width = | | Width = | ||
| Caption = Urothelial carcinoma at a surgical margin. [[H&E stain]]. | | Caption = Urothelial carcinoma at a [[surgical margin]]. [[H&E stain]]. | ||
| Synonyms = urothelial cell carcinoma | | Synonyms = urothelial cell carcinoma | ||
| Micro = | | Micro = | ||
| Subtypes = microcystic, glandular, inverted (growth pattern), nested | | Subtypes = [[microcystic urothelial carcinoma|microcystic]], [[micropapillary urothelial carcinoma|micropapillary]], glandular, inverted (growth pattern), [[nested urothelial carcinoma|nested]], papillary (dealt with separately in ''[[high-grade papillary urothelial carcinoma]]'' and ''[[low-grade papillary urothelial carcinoma]]''), [[plasmacytoid urothelial carcinoma]], others | ||
| LMDDx = [[urothelial carcinoma in situ]], metastatic carcinoma ([[prostate carcinoma]], [[colorectal carcinoma]]), [[inverted urothelial papilloma]] (for UCC with inverted growth pattern) | | LMDDx = [[urothelial carcinoma in situ]], metastatic carcinoma ([[prostate carcinoma]], [[colorectal carcinoma]]), [[inverted urothelial papilloma]] (for UCC with inverted growth pattern), [[epithelioid angiosarcoma]] | ||
| Stains = | | Stains = | ||
| IHC = [[GATA3]] +ve, p63 +ve, CK5/6 +ve, CK34betaE12 +ve, PSA -ve | | IHC = [[GATA3]] +ve, p63 +ve, CK5/6 +ve, CK34betaE12 +ve, PSA -ve | ||
| EM = | | EM = | ||
| Molecular = not used for diagnosis; typically: 9p deletions, 17p deletions | | Molecular = not used for diagnosis; typically: 9p deletions, 17p deletions; can be [[Classification of urothelial carcinoma by immunohistochemistry|subclassified with IHC]]; [[FGFR2/FGFR3]] mutations | ||
| IF = | | IF = | ||
| Gross = | | Gross = | ||
| Grossing = | | Grossing = [[transurethral resection of bladder tumour grossing]], [[radical cystectomy grossing]], [[cystoprostatectomy grossing]], [[nephroureterectomy grossing]] | ||
| Site = [[urothelium]] - [[ureter]], [[urinary bladder]], proximal urethra ( | | Staging = [[bladder cancer staging]] | ||
| Site = [[urothelium]] - [[ureter]], [[urinary bladder]], proximal [[urethra]] (see [[urothelial carcinoma of the urethra]], renal pelvis | |||
| Assdx = | | Assdx = | ||
| Syndromes = [[Lynch syndrome]] - esp. ureters | | Syndromes = [[Lynch syndrome]] - esp. ureters | ||
Line 38: | Line 39: | ||
See ''[[Urine_cytopathology#Urothelial_cell_carcinoma|urine cytology]]'' for the [[cytopathology]]. | See ''[[Urine_cytopathology#Urothelial_cell_carcinoma|urine cytology]]'' for the [[cytopathology]]. | ||
=General= | |||
*These lesions lack papillae and are typical flat. | *These lesions lack papillae and are typical flat. | ||
*Clinically, it may not be possible to differentiate renal pelvis urothelial carcinoma and [[renal cell carcinoma]]. | *Clinically, it may not be possible to differentiate renal pelvis urothelial carcinoma and [[renal cell carcinoma]]. | ||
Line 46: | Line 47: | ||
*Women often have worse outcomes as they present with more advanced tumours.<ref name=pmid24239476>{{Cite journal | last1 = Mitra | first1 = AP. | last2 = Skinner | first2 = EC. | last3 = Schuckman | first3 = AK. | last4 = Quinn | first4 = DI. | last5 = Dorff | first5 = TB. | last6 = Daneshmand | first6 = S. | title = Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a critical analysis of 1,994 patients. | journal = Urol Oncol | volume = 32 | issue = 1 | pages = 52.e1-9 | month = Jan | year = 2014 | doi = 10.1016/j.urolonc.2013.08.007 | PMID = 24239476 }}</ref> | *Women often have worse outcomes as they present with more advanced tumours.<ref name=pmid24239476>{{Cite journal | last1 = Mitra | first1 = AP. | last2 = Skinner | first2 = EC. | last3 = Schuckman | first3 = AK. | last4 = Quinn | first4 = DI. | last5 = Dorff | first5 = TB. | last6 = Daneshmand | first6 = S. | title = Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a critical analysis of 1,994 patients. | journal = Urol Oncol | volume = 32 | issue = 1 | pages = 52.e1-9 | month = Jan | year = 2014 | doi = 10.1016/j.urolonc.2013.08.007 | PMID = 24239476 }}</ref> | ||
*Positive soft tissue [[margin status|margin]].<ref name=pmid17936804>{{Cite journal | last1 = Dotan | first1 = ZA. | last2 = Kavanagh | first2 = K. | last3 = Yossepowitch | first3 = O. | last4 = Kaag | first4 = M. | last5 = Olgac | first5 = S. | last6 = Donat | first6 = M. | last7 = Herr | first7 = HW. | title = Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. | journal = J Urol | volume = 178 | issue = 6 | pages = 2308-12; discussion 2313 | month = Dec | year = 2007 | doi = 10.1016/j.juro.2007.08.023 | PMID = 17936804 }}</ref> | *Positive soft tissue [[margin status|margin]].<ref name=pmid17936804>{{Cite journal | last1 = Dotan | first1 = ZA. | last2 = Kavanagh | first2 = K. | last3 = Yossepowitch | first3 = O. | last4 = Kaag | first4 = M. | last5 = Olgac | first5 = S. | last6 = Donat | first6 = M. | last7 = Herr | first7 = HW. | title = Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. | journal = J Urol | volume = 178 | issue = 6 | pages = 2308-12; discussion 2313 | month = Dec | year = 2007 | doi = 10.1016/j.juro.2007.08.023 | PMID = 17936804 }}</ref> | ||
**Definition (radical cystectomy): tumour touching ink. | **Definition (radical cystectomy): tumour touching [[ink]]. | ||
Risk factors: | Risk factors: | ||
Line 54: | Line 55: | ||
*Others. | *Others. | ||
=Microscopic= | |||
Features: | Features: | ||
*Nuclear pleomorphism - '''key feature'''. | *Nuclear pleomorphism - '''key feature'''. | ||
Line 77: | Line 78: | ||
*[[High-grade papillary urothelial carcinoma]]. | *[[High-grade papillary urothelial carcinoma]]. | ||
*[[Low-grade papillary urothelial carcinoma]]. | *[[Low-grade papillary urothelial carcinoma]]. | ||
*[[Prostate carcinoma]]. | *[[Prostate carcinoma]] - may have pseudopapillae<ref name=pmid24503758>{{cite journal |author=Gordetsky J, Epstein JI |title=Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall |journal=Am. J. Surg. Pathol. |volume=38 |issue=7 |pages=941–5 |year=2014 |month=July |pmid=24503758 |doi=10.1097/PAS.0000000000000178 |url=}}</ref> - see ''[[urothelial carcinoma-like prostatic carcinoma]]''. | ||
*[[Epithelioid angiosarcoma]] - have intracytoplasmic lumens and interspersed red blood cells, usually have a history radiation treatment.<ref name=pmid25929352>{{cite journal |authors=Matoso A, Epstein JI |title=Epithelioid Angiosarcoma of the Bladder: A Series of 9 Cases |journal=Am J Surg Pathol |volume=39 |issue=10 |pages=1377–82 |date=October 2015 |pmid=25929352 |doi=10.1097/PAS.0000000000000444 |url=}}</ref> | |||
==Staging== | |||
{{Main|Bladder cancer staging}} | |||
*T1 - lamina propria. | *T1 - lamina propria. | ||
**Several subdivisions of T1 exist: | **Several subdivisions of T1 exist: | ||
Line 90: | Line 93: | ||
**In approximately 15% of cases it is pT0 (no primary tumour identified). | **In approximately 15% of cases it is pT0 (no primary tumour identified). | ||
===Muscularis propria invasion=== | |||
{{Main|Muscularis propria invasion in the urinary bladder}} | |||
==Images== | |||
== | |||
<gallery> | <gallery> | ||
Image: Urothelial carcinoma positive margin -- intermed mag.jpg | Typical UCC pos. margin - intermed. mag. | Image: Urothelial carcinoma positive margin -- intermed mag.jpg | Typical UCC pos. margin - intermed. mag. | ||
Line 179: | Line 103: | ||
Image: Urothelial carcinoma positive margin - alt -- intermed mag.jpg | Typical UCC pos. margin - intermed. mag. | Image: Urothelial carcinoma positive margin - alt -- intermed mag.jpg | Typical UCC pos. margin - intermed. mag. | ||
Image: Urothelial carcinoma positive margin - alt -- high mag.jpg | Typical UCC pos. margin - high mag. | Image: Urothelial carcinoma positive margin - alt -- high mag.jpg | Typical UCC pos. margin - high mag. | ||
</gallery> | </gallery> | ||
www: | www: | ||
*[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3282447/figure/F2/ Several images of NUCC (nih.gov)].<ref name=pmid22355497>{{Cite journal | last1 = Terada | first1 = T. | title = Nested variant of urothelial carcinoma of the urinary bladder. | journal = Rare Tumors | volume = 3 | issue = 4 | pages = e42 | month = Oct | year = 2011 | doi = 10.4081/rt.2011.e42 | PMID = 22355497 | PMC = 3282447 }}</ref> | *[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3282447/figure/F2/ Several images of NUCC (nih.gov)].<ref name=pmid22355497>{{Cite journal | last1 = Terada | first1 = T. | title = Nested variant of urothelial carcinoma of the urinary bladder. | journal = Rare Tumors | volume = 3 | issue = 4 | pages = e42 | month = Oct | year = 2011 | doi = 10.4081/rt.2011.e42 | PMID = 22355497 | PMC = 3282447 }}</ref> | ||
[[File:5 410253052 sl 1.png| High grade urothelial carcinoma]] | |||
[[File:5 410253052 sl 2.png| High grade urothelial carcinoma]] | |||
[[File:5 410253052 sl 3.png| High grade urothelial carcinoma]] | |||
[[File:5 410253052 sl 4.png| High grade urothelial carcinoma]] | |||
[[File:5 410253052 sl 5.png| High grade urothelial carcinoma]] | |||
[[File:5 410253052 sl 6.png| High grade urothelial carcinoma]] | |||
[[File:5 410253052 sl 7.png| High grade urothelial carcinoma]] | |||
[[File:5 410253052 sl 8.png| High grade urothelial carcinoma]]<br> | |||
High grade urothelial carcinoma in a 43 year old man. A. At low power, necrosis is seen, luminal, with viable invasive tumor elsewhere. B. Tumor partly fills right ureteral orifice. C. Tumor cells sometimes form Indian files (black arrows), appear to have nuclei that mold (red arrows), and have granular chromatin (cyan arrows), raising possibility of neuroendocrine carcinoma. D. Tumor invades lymphatic spaces. E. Urothelial carcinoma in situ is present. F,G,H. Tumor cells are diffusely positive for CK7, focally positive for CDX2, and diffusely positive for P40, with no positivity for chromogranin or synaptophysin. | |||
=[[IHC]]= | |||
Recommended by [[ISUP]] consensus panel:<ref name=pmid25025364 >{{cite journal |author=Amin MB, Epstein JI, Ulbright TM, ''et al.'' |title=Best practices recommendations in the application of immunohistochemistry in urologic pathology: report from the international society of urological pathology consensus conference |journal=Am. J. Surg. Pathol. |volume=38 |issue=8 |pages=1017–22 |year=2014 |month=August |pmid=25025364 |doi=10.1097/PAS.0000000000000254 |url=}}</ref> | Recommended by [[ISUP]] consensus panel:<ref name=pmid25025364 >{{cite journal |author=Amin MB, Epstein JI, Ulbright TM, ''et al.'' |title=Best practices recommendations in the application of immunohistochemistry in urologic pathology: report from the international society of urological pathology consensus conference |journal=Am. J. Surg. Pathol. |volume=38 |issue=8 |pages=1017–22 |year=2014 |month=August |pmid=25025364 |doi=10.1097/PAS.0000000000000254 |url=}}</ref> | ||
*GATA3 +ve, CK20 +ve, p63 +ve, CK5/6, HMWCK (e.g. CK34betaE12) +ve. | *GATA3 +ve, CK20 +ve, p63 +ve, CK5/6, HMWCK (e.g. CK34betaE12) +ve. | ||
Line 202: | Line 131: | ||
:''See [[urothelial carcinoma in situ]]''. | :''See [[urothelial carcinoma in situ]]''. | ||
===UCC versus other=== | ===UCC versus other cancers=== | ||
UCC vs. [[Prostate cancer|prostate]]: | UCC vs. [[Prostate cancer|prostate]]: | ||
*UCC: GATA3 +ve, PSA -ve, p63 +ve, CK20 +ve. | *UCC: GATA3 +ve, PSA -ve, [[p63]] +ve, [[CK20]] +ve. | ||
*Prostate: PSA +ve, GATA3 -ve, PSAP +ve, CK7 -ve, CK20 -ve, p63 -ve. | *Prostate: [[PSA]] +ve, [[GATA3]] -ve, [[PSAP]] +ve, CK7 -ve, CK20 -ve, p63 -ve. | ||
UCC vs. [[renal cell carcinoma| | UCC vs. [[renal cell carcinoma|renal cell carcinoma]]: | ||
*UCC: p63 +ve.<ref>{{Cite journal | last1 = Langner | first1 = C. | last2 = Ratschek | first2 = M. | last3 = Tsybrovskyy | first3 = O. | last4 = Schips | first4 = L. | last5 = Zigeuner | first5 = R. | title = P63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors. | journal = J Histochem Cytochem | volume = 51 | issue = 8 | pages = 1097-9 | month = Aug | year = 2003 | doi = | PMID = 12871991 }} | *UCC: p63 +ve.<ref>{{Cite journal | last1 = Langner | first1 = C. | last2 = Ratschek | first2 = M. | last3 = Tsybrovskyy | first3 = O. | last4 = Schips | first4 = L. | last5 = Zigeuner | first5 = R. | title = P63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors. | journal = J Histochem Cytochem | volume = 51 | issue = 8 | pages = 1097-9 | month = Aug | year = 2003 | doi = | PMID = 12871991 }} | ||
</ref> | </ref> | ||
Metastatic UCC versus primary lung squamous cell carcinoma: | |||
:See ''[[Squamous_cell_carcinoma_of_the_lung#Lung_SCC_versus_metastatic_bladder_urothelial_carcinoma]]''. | |||
Note: | Note: | ||
Line 216: | Line 148: | ||
**In half the cases the staining is weak and in the other half it is strong.<ref name=pmid19192675/> | **In half the cases the staining is weak and in the other half it is strong.<ref name=pmid19192675/> | ||
=== | ===IHC for staging=== | ||
*''Smoothelin'' immunostain for [[bladder muscularis propria invasion|muscularis propria invasion]] versus muscularis mucosae invasion - see ''[[Muscularis_propria_invasion_in_the_urinary_bladder#IHC]]''. | |||
=Molecular= | |||
*Molecular testing usually ''not'' used for diagnosis. | |||
**Molecular subtyping can be approximated with immunostaining - see ''[[Classification of urothelial carcinoma by immunohistochemistry]]''. | |||
Changes: | Changes: | ||
Line 231: | Line 159: | ||
*17p deletion -- site of PT53 (AKA p53). | *17p deletion -- site of PT53 (AKA p53). | ||
=Sign out= | |||
==High grade UC== | |||
<pre> | <pre> | ||
URINARY BLADDER LESION ("TUMOUR"), TRANSURETHRAL RESECTION URINARY BLADDER TUMOUR (TURBT): | URINARY BLADDER LESION ("TUMOUR"), TRANSURETHRAL RESECTION URINARY BLADDER TUMOUR (TURBT): | ||
Line 240: | Line 168: | ||
</pre> | </pre> | ||
==UCC with some suspicion for muscularis propria invasion== | |||
<pre> | <pre> | ||
URINARY BLADDER LESION ("TUMOUR"), DEEP, RE-RESECTION (TURBT): | URINARY BLADDER LESION ("TUMOUR"), DEEP, RE-RESECTION (TURBT): | ||
Line 263: | Line 183: | ||
</pre> | </pre> | ||
===Alternate comment=== | |||
<pre> | <pre> | ||
The sections shows thickened muscle bundles with frayed edges between the | The sections shows thickened muscle bundles with frayed edges between the | ||
Line 271: | Line 191: | ||
</pre> | </pre> | ||
==See also | =Subtypes of urothelial carcinoma= | ||
There are numerous subtypes:<ref>URL: [http://www.nature.com/modpathol/journal/v22/n2s/full/modpathol200926a.html http://www.nature.com/modpathol/journal/v22/n2s/full/modpathol200926a.html]. Accessed on: 19 August 2011.</ref> | |||
*Squamous differentiation. | |||
*Clear cell. | |||
*[[Plasmacytoid urothelial carcinoma|Plasmacytoid]]. | |||
*[[Micropapillary urothelial carcinoma|Micropapillary]]. | |||
**Small nests (< ~10 cells/nest). | |||
*Sarcomatoid. | |||
**Images: [http://path.upmc.edu/cases/case615.html UCC with sarcomatoid differentiation (upmc.edu)]. | |||
*Many others... | |||
Benign patterns - mnemonic ''Much GIN'': | |||
*'''M'''icrocystic. | |||
*Small tubular/'''g'''landular. | |||
*'''I'''nverted. | |||
*'''N'''ested. | |||
==Plasmacytoid urothelial cell carcinoma== | |||
{{Main|Plasmacytoid urothelial carcinoma}} | |||
==Microcystic urothelial carcinoma== | |||
{{Main|Microcystic urothelial carcinoma}} | |||
==Micropapillary urothelial carcinoma== | |||
{{Main|Micropapillary urothelial carcinoma}} | |||
==Lymphoepithelioma-like carcinoma== | |||
{{Main|Lymphoepithelioma-like carcinoma of the urinary bladder}} | |||
==Nested urothelial cell carcinoma== | |||
*[[AKA]] ''nested variant of urothelial cell carcinoma''. | |||
{{Main|Nested urothelial carcinoma}} | |||
=See also= | |||
*[[Urothelium]]. | *[[Urothelium]]. | ||
*[[Urothelial dysplasia]]. | *[[Urothelial dysplasia]]. | ||
Line 277: | Line 230: | ||
*[[Prostatic urothelial carcinoma]]. | *[[Prostatic urothelial carcinoma]]. | ||
=References= | |||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Urothelium]] | [[Category:Urothelium]] | ||
[[Category:Diagnosis]] | [[Category:Diagnosis]] |
Latest revision as of 12:54, 13 June 2024
Urothelial carcinoma, also urothelial cell carcinoma, is a malignancy that arises from the urothelium. Urothelial carcinoma is abbreviated UC and urothelial cell carcinoma is abbreviated UCC.
This article deals with flat invasive urothelial carcinoma. The direct precursor is dealt with in urothelial carcinoma in situ.
Papillary urothelial carcinomas are dealt with in low-grade papillary urothelial carcinoma and high-grade papillary urothelial carcinoma.
See urine cytology for the cytopathology.
General
- These lesions lack papillae and are typical flat.
- Clinically, it may not be possible to differentiate renal pelvis urothelial carcinoma and renal cell carcinoma.
- May be a part of Lynch syndrome.
Prognosis:
- Women often have worse outcomes as they present with more advanced tumours.[1]
- Positive soft tissue margin.[2]
- Definition (radical cystectomy): tumour touching ink.
Risk factors:
- Smoking.
- Toxins.
- Drugs, e.g. cyclophosphamide.
- Others.
Microscopic
Features:
- Nuclear pleomorphism - key feature.
- Compare nuclei to one another.
- Increased N/C ratio.
- Lack of maturation to surface (important).
- Cells become dyscohesive.
Invasion vs. in situ: Useful features - present in invasion:[3]
- Thin-walled vessels.
- Stromal reaction (hypercellularity).
- Retraction artefact around the tumour cell nests.
Note:
- The presence/absence of muscle should be commented on in biopsy specimens.
- Adipose tissue may be seen in the lamina propria; tumour adjacent to adipose tissue on a biopsy does not imply invasion deep to the muscularis propria.[4]
DDx:
- Pseudocarcinomatous urothelial hyperplasia.
- Urothelial carcinoma in situ.
- High-grade papillary urothelial carcinoma.
- Low-grade papillary urothelial carcinoma.
- Prostate carcinoma - may have pseudopapillae[5] - see urothelial carcinoma-like prostatic carcinoma.
- Epithelioid angiosarcoma - have intracytoplasmic lumens and interspersed red blood cells, usually have a history radiation treatment.[6]
Staging
- T1 - lamina propria.
- Several subdivisions of T1 exist:
- T1a - superficial or in muscularis mucosae.
- T1b - beyond muscularis mucosae - into submucosa.
- Several subdivisions of T1 exist:
- T2 - muscularis propria.
Note:
- Approximately 25% of muscle invasive urothelial carcinoma on biopsy is a lower stage in the cystectomy specimen.[7]
- In approximately 15% of cases it is pT0 (no primary tumour identified).
Muscularis propria invasion
Images
www:
High grade urothelial carcinoma in a 43 year old man. A. At low power, necrosis is seen, luminal, with viable invasive tumor elsewhere. B. Tumor partly fills right ureteral orifice. C. Tumor cells sometimes form Indian files (black arrows), appear to have nuclei that mold (red arrows), and have granular chromatin (cyan arrows), raising possibility of neuroendocrine carcinoma. D. Tumor invades lymphatic spaces. E. Urothelial carcinoma in situ is present. F,G,H. Tumor cells are diffusely positive for CK7, focally positive for CDX2, and diffusely positive for P40, with no positivity for chromogranin or synaptophysin.
IHC
Recommended by ISUP consensus panel:[9]
- GATA3 +ve, CK20 +ve, p63 +ve, CK5/6, HMWCK (e.g. CK34betaE12) +ve.
Others:
- CK7 +ve.
- PSA -ve.
Notes:
- CK20 negative in over 50% of cases with metastases.[10]
Reactive changes versus UCIS
UCC versus other cancers
UCC vs. prostate:
- UCC: GATA3 +ve, PSA -ve, p63 +ve, CK20 +ve.
- Prostate: PSA +ve, GATA3 -ve, PSAP +ve, CK7 -ve, CK20 -ve, p63 -ve.
UCC vs. renal cell carcinoma:
- UCC: p63 +ve.[11]
Metastatic UCC versus primary lung squamous cell carcinoma:
Note:
- In a large series, PSA positivity is reported in 1.4% bladder UCC.[12]
- In half the cases the staining is weak and in the other half it is strong.[12]
IHC for staging
- Smoothelin immunostain for muscularis propria invasion versus muscularis mucosae invasion - see Muscularis_propria_invasion_in_the_urinary_bladder#IHC.
Molecular
- Molecular testing usually not used for diagnosis.
- Molecular subtyping can be approximated with immunostaining - see Classification of urothelial carcinoma by immunohistochemistry.
Changes:
- 9p deletion -- site of CDKN2A[13] (AKA p16).
- 17p deletion -- site of PT53 (AKA p53).
Sign out
High grade UC
URINARY BLADDER LESION ("TUMOUR"), TRANSURETHRAL RESECTION URINARY BLADDER TUMOUR (TURBT): - INVASIVE HIGH-GRADE PAPILLARY UROTHELIAL CARCINOMA WITH SQUAMOUS DIFFERENTIATION AT LEAST INTO MUSCULARIS PROPRIA. - LYMPHOVASCULAR INVASION PRESENT.
UCC with some suspicion for muscularis propria invasion
URINARY BLADDER LESION ("TUMOUR"), DEEP, RE-RESECTION (TURBT): - INVASIVE HIGH-GRADE UROTHELIAL CARCINOMA WITH SQUAMOUS DIFFERENTIATION AT LEAST INTO THE LAMINA PROPRIA, SEE COMMENT. - NO DEFINITE LYMPHOVASCULAR INVASION. COMMENT: Tumour is seen adjacent to smooth muscle fibres of intermediate thickness. This is interpreted as thick muscularis mucosae. The tissue orientation is suboptimal. Definite muscularis propria is not apparent. Levels were cut. Tumour is abundant in the lamina propria.
Alternate comment
The sections shows thickened muscle bundles with frayed edges between the tumour cells. The muscle is thought to represent hypertrophic muscularis mucosae. The large extent of lamina propria invasion raises the possibility of a higher stage lesion that may not have been sampled.
Subtypes of urothelial carcinoma
There are numerous subtypes:[14]
- Squamous differentiation.
- Clear cell.
- Plasmacytoid.
- Micropapillary.
- Small nests (< ~10 cells/nest).
- Sarcomatoid.
- Many others...
Benign patterns - mnemonic Much GIN:
- Microcystic.
- Small tubular/glandular.
- Inverted.
- Nested.
Plasmacytoid urothelial cell carcinoma
Microcystic urothelial carcinoma
Micropapillary urothelial carcinoma
Lymphoepithelioma-like carcinoma
Nested urothelial cell carcinoma
- AKA nested variant of urothelial cell carcinoma.
See also
References
- ↑ Mitra, AP.; Skinner, EC.; Schuckman, AK.; Quinn, DI.; Dorff, TB.; Daneshmand, S. (Jan 2014). "Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a critical analysis of 1,994 patients.". Urol Oncol 32 (1): 52.e1-9. doi:10.1016/j.urolonc.2013.08.007. PMID 24239476.
- ↑ Dotan, ZA.; Kavanagh, K.; Yossepowitch, O.; Kaag, M.; Olgac, S.; Donat, M.; Herr, HW. (Dec 2007). "Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival.". J Urol 178 (6): 2308-12; discussion 2313. doi:10.1016/j.juro.2007.08.023. PMID 17936804.
- ↑ Sternberg, SE. Histology for Pathologists. P.2047.
- ↑ Bochner, BH.; Nichols, PW.; Skinner, DG. (Mar 1995). "Overstaging of transitional cell carcinoma: clinical significance of lamina propria fat within the urinary bladder.". Urology 45 (3): 528-31. doi:10.1016/S0090-4295(99)80030-2. PMID 7879346.
- ↑ Gordetsky J, Epstein JI (July 2014). "Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall". Am. J. Surg. Pathol. 38 (7): 941–5. doi:10.1097/PAS.0000000000000178. PMID 24503758.
- ↑ Matoso A, Epstein JI (October 2015). "Epithelioid Angiosarcoma of the Bladder: A Series of 9 Cases". Am J Surg Pathol 39 (10): 1377–82. doi:10.1097/PAS.0000000000000444. PMID 25929352.
- ↑ D'Souza, AM.; Pohar, KS.; Arif, T.; Geyer, S.; Zynger, DL. (Oct 2012). "Retrospective analysis of survival in muscle-invasive bladder cancer: impact of pT classification, node status, lymphovascular invasion, and neoadjuvant chemotherapy.". Virchows Arch 461 (4): 467-74. doi:10.1007/s00428-012-1249-4. PMID 22915241.
- ↑ Terada, T. (Oct 2011). "Nested variant of urothelial carcinoma of the urinary bladder.". Rare Tumors 3 (4): e42. doi:10.4081/rt.2011.e42. PMC 3282447. PMID 22355497. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3282447/.
- ↑ Amin MB, Epstein JI, Ulbright TM, et al. (August 2014). "Best practices recommendations in the application of immunohistochemistry in urologic pathology: report from the international society of urological pathology consensus conference". Am. J. Surg. Pathol. 38 (8): 1017–22. doi:10.1097/PAS.0000000000000254. PMID 25025364.
- ↑ Jiang, J.; Ulbright, TM.; Younger, C.; Sanchez, K.; Bostwick, DG.; Koch, MO.; Eble, JN.; Cheng, L. (Jul 2001). "Cytokeratin 7 and cytokeratin 20 in primary urinary bladder carcinoma and matched lymph node metastasis.". Arch Pathol Lab Med 125 (7): 921-3. doi:10.1043/0003-9985(2001)1250921:CACIPU2.0.CO;2. PMID 11419977.
- ↑ Langner, C.; Ratschek, M.; Tsybrovskyy, O.; Schips, L.; Zigeuner, R. (Aug 2003). "P63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors.". J Histochem Cytochem 51 (8): 1097-9. PMID 12871991.
- ↑ 12.0 12.1 Chen, JC.; Ho, CL.; Tsai, HW.; Tzai, TS.; Liu, HS.; Chow, NH.; Yang, WH.; Cheng, HL.. "Immunohistochemical detection of prostate-specific antigen expression in primary urothelial carcinoma of the urinary bladder.". Anticancer Res 28 (6B): 4149-54. PMID 19192675.
- ↑ Online 'Mendelian Inheritance in Man' (OMIM) 600160
- ↑ URL: http://www.nature.com/modpathol/journal/v22/n2s/full/modpathol200926a.html. Accessed on: 19 August 2011.